Last updated: October 7, 2023
Sponsor: The Second Hospital of Nanjing Medical University
Overall Status: Completed
Phase
N/A
Condition
Autism
Asperger's Disorder
Autism Spectrum Disorder (Asd)
Treatment
Esketamine
Propofol
Clinical Study ID
NCT05951465
esketamine 2023 N002
Ages 3-14 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- (1) aged 2-12 years;
- (2) diagnosed with ASD by pediatric psychiatrists in accordance with the criteria inthe Fifth Edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-V);
- (3) evaluated as American Society of Anesthesiologists (ASA) physical status I-II;
- (4) scheduled for colonic procedure.
Exclusion
Exclusion Criteria:
- (1) oral sedation (premedication) before intravenous catheter placement;
- (2) any contraindication to study medications;
- (3) other circumstances in which the investigator determined that a patient was notsuitable for participation in the clinical trial.
Study Design
Total Participants: 46
Treatment Group(s): 2
Primary Treatment: Esketamine
Phase:
Study Start date:
July 20, 2023
Estimated Completion Date:
September 20, 2023
Study Description
Connect with a study center
Sir Run Run Hospital
Nanjing, Jiangsu 210000
ChinaSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.